Loading the dossier
The Hill Wire · Member dossier
Brad Knott
RepublicanRepresentative · NC-13Current term began Jan 2025⚑ Habitual late filer: median 46 days before a trade was made publicQuiet since Feb 2025
Ethics
Fewer than five priced purchases on the record, so no comparison to the index is drawn.
- Disclosed trades
- 3
- 2 purchases · 1 sale · made public since January 2025
- Disclosed volume
- $49K
- midpoints of the reported ranges, not what Knott owns
- Made public
- 46 days
- Half of Knott's trades were made public within 46 days; Congress overall 28; the law allows 45.
- On time
- 33%
- 79% across Congress
Brad Knott represents North Carolina's 13th congressional district in the House and previously worked as a federal prosecutor
Brad Knott is an attorney and politician. Before taking office in 2025, he worked as a federal prosecutor in the office of the United States attorney for the Eastern District of North Carolina. He represents North Carolina's 13th congressional district in the United States House of Representatives.
His federal prosecution background provides experience in law and government. His committee assignments cover transportation, infrastructure, the judiciary and homeland security, providing context across aviation, water resources and transit.
attorney · former federal prosecutor
Generated with AI, awaiting an editor · from Wikipedia · not from the filings
What the filings show
A North Carolina House Republican whose disclosed stock activity is narrowly concentrated and often reported late
The limited record cannot establish an investment approach, though buying and selling have been frequent within the disclosed period. Activity is tightly concentrated in Oramed Pharmaceuticals and CompoSecure common stock, with no funds or options disclosed. The accounts are almost entirely in Knott's own name.
What to watch
- Late reporting is recurrent, making the delay between a trade and its disclosure a central concern.
- Oramed Pharmaceuticals accounts for most disclosed dollar activity; new names could broaden the narrow mix.
- Further technology trades would extend the overlap with his committee responsibilities.
Generated with AI, awaiting an editor, from the member’s own filings · carries no figures and makes no claim about performance
Public information from STOCK Act filings. Amounts are reported in ranges and shown as midpoints, filings arrive after the trades, and no personal profit or loss is disclosed. Not financial advice.